Chimeric Antigen Receptor (CAR) T-cell Therapy

N/A

Report date: 2024/04/24 20:00:35

Base Information

Drug NameChimeric Antigen Receptor (CAR) T-cell Therapy
Drug Alias NameTranspoCART19TranspoCART-19
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy > Gene editing > Sleeping Beauty transposon/transposase systemCell and gene therapy > Cell therapy > Donor > Autologous +[4] 
Mechanisms of ActionAnti-CD19T lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySpain
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesInstituto De Investigación Biomédica De SalamancaFundacion Canaria De Investigacion SanitariaSpanish Clinical Research Network (SCReN)
China Registration ClassN/A

Develop Information

Active CompaniesSpanish Clinical Research Network (SCReN)Instituto De Investigación Biomédica De SalamancaFundacion Canaria De Investigacion Sanitaria
Inactive CompaniesN/A
Active IndicationsLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A